TGFB1 and diabetes mellitus: A study revealed that soluble guanylate cyclase activator cinaciguat treatment restored the glomerular cGMP content and soluble guanylate cyclase expression, improved diabetes-induced glomerular damage, apoptosis, podocyte injury, proteinuria, and TIMP-1 overexpression by suppressing TGF-β and ERK1/2 signaling [48].